Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF N486_P490del |
| Therapy | LY3009120 + Trametinib |
| Indication/Tumor Type | pancreatic ductal adenocarcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF N486_P490del | pancreatic ductal adenocarcinoma | sensitive | LY3009120 + Trametinib | Preclinical - Pdx | Actionable | In a preclinical study, a patient-derived xenograft (PDX) model with pancreatic ductal adenocarcinoma harboring BRAF N486_P490del demonstrated inhibition of Erk phosphorylation and greater inhibition of tumor growth when treated with the combination of Mekinist (trametinib) and LY3009120 compared to either agent alone (PMID: 34011980). | 34011980 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (34011980) | Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers. | Full reference... |